Cellectis Sa Stock Performance
| CMVLF Stock | USD 2.58 1.33 106.40% |
Cellectis holds a performance score of 9 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.86, which signifies possible diversification benefits within a given portfolio. Cellectis returns are very sensitive to returns on the market. As the market goes up or down, Cellectis is expected to follow. Use Cellectis total risk alpha, as well as the relationship between the rate of daily change and period momentum indicator , to analyze future returns on Cellectis.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Cellectis SA are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile essential indicators, Cellectis reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 241.1 M | |
| Total Cashflows From Investing Activities | 7.3 M |
Cellectis |
Cellectis Relative Risk vs. Return Landscape
If you would invest 125.00 in Cellectis SA on April 28, 2025 and sell it today you would earn a total of 133.00 from holding Cellectis SA or generate 106.4% return on investment over 90 days. Cellectis SA is currently producing 1.6889% returns and takes up 13.4051% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Cellectis, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Cellectis Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cellectis' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Cellectis SA, and traders can use it to determine the average amount a Cellectis' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.126
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | CMVLF | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 13.41 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.69 actual daily | 34 66% of assets have higher returns |
Risk-Adjusted Return
| 0.13 actual daily | 9 91% of assets perform better |
Based on monthly moving average Cellectis is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cellectis by adding it to a well-diversified portfolio.
Cellectis Fundamentals Growth
Cellectis Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Cellectis, and Cellectis fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cellectis Pink Sheet performance.
| Return On Equity | -0.56 | |||
| Return On Asset | -0.24 | |||
| Operating Margin | (6.01) % | |||
| Current Valuation | 82.79 M | |||
| Shares Outstanding | 55.59 M | |||
| Price To Earning | (13.64) X | |||
| Price To Book | 0.79 X | |||
| Price To Sales | 4.79 X | |||
| Revenue | 57.29 M | |||
| EBITDA | (103.2 M) | |||
| Cash And Equivalents | 153.13 M | |||
| Cash Per Share | 3.37 X | |||
| Total Debt | 18.77 M | |||
| Debt To Equity | 0.52 % | |||
| Book Value Per Share | 3.00 X | |||
| Cash Flow From Operations | (104.56 M) | |||
| Earnings Per Share | (2.95) X | |||
| Total Asset | 382.08 M | |||
| Retained Earnings | (206 M) | |||
| Current Asset | 297 M | |||
| Current Liabilities | 58 M | |||
About Cellectis Performance
By analyzing Cellectis' fundamental ratios, stakeholders can gain valuable insights into Cellectis' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cellectis has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cellectis has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. Cellectis Romainvil operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 294 people.Things to note about Cellectis SA performance evaluation
Checking the ongoing alerts about Cellectis for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Cellectis SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cellectis SA is way too risky over 90 days horizon | |
| Cellectis SA appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 57.29 M. Net Loss for the year was (114.2 M) with profit before overhead, payroll, taxes, and interest of 34.18 M. | |
| Cellectis SA has accumulated about 153.13 M in cash with (104.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.37, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Cellectis' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cellectis' stock is overvalued or undervalued compared to its peers.
- Examining Cellectis' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cellectis' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cellectis' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cellectis' pink sheet. These opinions can provide insight into Cellectis' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cellectis Pink Sheet analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Commodity Directory Find actively traded commodities issued by global exchanges |